Annual Review Course Webcast (2017): Erectile Dysfunction

In preparation for the American Board of Urology (ABU) Qualifying (Part 1) Examination, residents need to have basic urologic knowledge to prepare them for the ABU examinations. To fulfill this need, the American Urological Association (AUA) developed this course to disseminate current urologic knowledge. This course is also of interest to practicing urologist preparing for the Recertification Examination as well as others, including allied health professionals, looking for a thorough review of basic urologic topics.

Target Audience

This course is designed for:

  • Residents preparing for Part I of the ABU Qualifying Examination

This course may also be of interest to:

  • Practicing urologists taking the Recertification Examination
  • Individuals looking to update or renew their knowledge base

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Apply basic, generally-accepted urological practices for superior patient care.
  2. Demonstrate core knowledge of urology necessary for Part I of the American Board of Urology (ABU) qualifying examination and for the recertification examination.
  3. Utilize AUA Guidelines for appropriate patient evaluation and management.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
06/13/2017
Course expires: 
06/13/2020
Rating: 
0

Faculty Disclosures
 
Course Co-Directors:
Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
Wade J. Sexton, MD: Nothing to disclose
 
Course Faculty:
Jay Todd Bishoff, MD: Myriad Genetics: Consultant or Advisor, Scientific Study or Trial
Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
Brian Herts, MD: Siemens Medical Solutions: Scientific Study or Trial
Duane R. Hickling, MD: Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Pfizer: Meeting Participant or Lecturer; Allergan: Consultant or Advisor, Meeting Participant or Lecturer
Adam Stuart Kibel MD: Sanofi-Aventis: Consultant or Advisor, Scientific Study or Trial; MTG: Consultant or Advisor; Profound: Consultant or Advisor; Dendreon: Consultant or Advisor
Andrew Jared Kirsch MD: Nothing to disclose
Stephen R. Kraus, MD: Laborie: Consultant or Advisor; Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Meeting Participant or Lecturer; InCube: Consultant or Advisor
Gary Evan Lemack ,MD: Astellas: Consultant or Advisor, Meeting Participant or Lecturer; Allergan: Consultant or Advisor, Meeting Participant or Lecturer; Medtronic: Consultant or Advisor
Seth Paul Lerner, MD, FACS: Endo Pharmaceutical: Scientific Study or Trial; FKD: Scientific Study or Trial; UroGen: Consultant or Advisor; Biocancell: Consultant or Advisor; Vaxxion: Consultant or Advisor; Nucleix: Consultant or Advisor; Viventia: Scientific Study or Trial; UpToDate: Health Publishing
Armando J. Lorenzo, MD,FAAP,FACS,FRCSC,MSC: Nothing to disclose
John Patrick Mulhall, MD: Association of Peyronie's Disease Advocates (APDA): Leadership Position; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Michael A. O'Donnell, MD: Viventia: Consultant or Advisor; Photocure: Scientific Study or Trial; Telesta: Consultant or Advisor; Genentech: Scientific Study or Trial; Medical Enterprises: Consultant or Advisor, Scientific Study or Trial; Theralase: Consultant or Advisor, Investment Interest; Spectrum Pharmaceuticals: Consultant or Advisor; Fidia Pharmaceuticals: Consultant or Advisor; Abbott Molecular: Scientific Study or Trial
Glenn M. Preminger, MD: Boston Scientific: Consultant or Advisor; Endourological Society: Leadership Position; UpToDate: Health Publishing; Retrophin: Consultant or Advisor, Meeting Participant or Lecturer
Peter Gerard Schulam, MD PHD: HUMM: Consultant or Advisor
Wade Jeffers Sexton, MD: Nothing to disclose
Daniel Arthur Shoskes MD: Triurol: Investment Interest; Farr Labs: Consultant or Advisor; Astellas: Consultant or Advisor; Aquinox: Consultant or Advisor
Jay Simhan: Boston Scientific: Meeting Participant or Lecturer; Coloplast: Meeting Participant or Lecturer
Paul Jacob Turek, MD: MandalMed: Leadership Position; Medical Board of California: Consultant or Advisor; HealthLoop.com: Consultant or Advisor, Investment Interest; Doximity, Inc: Consultant or Advisor, Investment Interest; Episona, Inc: Consultant or Advisor: Cellarity Biotechnologies, Inc: Leadership Position, Investment Interest, Owner, Product Development; BioQuiddity, Inc: Consultant or Advisor, Investment Interest; Essential Beginnings, Inc: Leadership Position, Investment Interest, Owner, Product Development
Robert G. Uzzo, MD: Janssen: Meeting Participant or Lecturer; Pfizer: Meeting Participant or Lecturer; Novartis: Scientific Study or Trial; Genentech: Scientific Study or Trial; GSK: Consultant or Advisor
 
Planner Disclosures
 
Education Council
Timothy Charles Brand, M.D.: Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
Matthew S. Christman MD: Nothing to disclose
Jody Donaldson: Nothing to disclose
Shelby Englert: Nothing to disclose
Matthew Thomas Gettman, MD: Nothing to disclose
Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
William C. Hulbert Jr. MD: Nothing to disclose
Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Consultant or Advisor; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
Mark L. Jordan MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle MD: Nothing to disclose
Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
Nicole Lara Miller ,MD: Present: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose
Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Consultant or Advisor, Scientific Study or Trial
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
Joseph A. Smith Jr.,MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
Edouard John Trabulsi, MD: Nothing to disclose
 

Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
 
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
 

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
 
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: cme@AUAnet.org

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation

Accreditation Period

Course opens: 
06/13/2017
Course expires: 
06/13/2020
Please login or register to take this course.